Adalimumab efficacy is inversely correlated with body mass index (BMI) in hidradenitis suppurativa.
Avigdor NosratiMcCall E TorpeyNeda ShokrianPeter Yi Ch'enTyler M AndrianoGabrielle BeneshHaley D HeibelH Dean HosgoodKristina L CamptonSteven R CohenPublished in: International journal of dermatology (2022)
We identified significantly lower efficacy of adalimumab in HS patients with BMI ≥ 30 compared to those with BMI < 30. Those with BMI ≥ 30 demonstrated signs of both clinical and physiological deterioration while on adalimumab. Future studies are needed to examine adalimumab dosing for HS patients with high BMI, as well as a critical reconsideration of weight-based therapies.